Enzyme-linked immunosorbent assay of phenolic glycolipid-I in patients with Hansen's disease
Introduction: Hansen′s disease or leprosy is a contagious-infection entity produced by the Hansen bacillus or Mycobacterium leprae. The phenolic glycolipid is a special trisaccharide found in the bacillus cell wall and proved to be specific and immunogenic species during M. leprae. Objective: To det...
Gespeichert in:
Veröffentlicht in: | Colombia médica (Cali, Colombia) Colombia), 2010-04, Vol.41 (2), p.155-160 |
---|---|
Hauptverfasser: | , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Introduction: Hansen′s disease or leprosy is a
contagious-infection entity produced by the Hansen bacillus or
Mycobacterium leprae. The phenolic glycolipid is a special
trisaccharide found in the bacillus cell wall and proved to be specific
and immunogenic species during M. leprae. Objective: To determine the
presence of the Hansen bacillus enzyme-linked immunoassay (ELISA)
method glycolipid phenolic I in a group of patients in Dermatology
Consultation at the Valle del Cauca Health Services; these patients
were classified as cures or under watch according to criteria
established by the World Health Organization (WHO). Methodology: From
the data base of the Dermatology Consultation at the Valle del Cauca
Health Services, we studied 159 patients with Hansen′s disease
who were tested with the enzyme-linked immunoassay (ELISA) with the
phenolic glycolipid I to cross reference information and observe if
they were or were not positive to this test. A positive ELISA indicates
the bacillus is still present in the patient. Results: As an important
fact, we found that of 78 patients cured, when bearing in mind the
monitoring period, 9 were positive for the ELISA. When this period was
discarded, 81 sick individuals were classified as cured according to
WHO criteria but the same 9 continued positive for ELISA. Conclusion:
It may be concluded that in spite of meeting WHO criteria, these
patients still show presence of the bacillus and the monitoring period
is not required as a criterion to discharge a patient. We recommend
adding to WHO criteria a negative ELISA, to obtain additional
information that helps to certify that a patient is or is not cured.
Introducción: La enfermedad de Hansen o lepra es una entidad
infecto-contagiosa producida por el bacilo de Hansen o Mycobacterium
leprae. El glicolípido fenólico I es un trisacárido
especial que se encuentra en la pared celular del bacilo y ha
demostrado ser específico de especie e inmunogénico durante
la infección de M. leprae. Objetivo: Determinar la presencia del
bacilo de Hansen por el método de inmunoensayo ligado a enzimas
(ELISA) a glicolípido fenólico I en un grupo de pacientes del
Consultorio Dermatológico del Servicio de Salud del Valle del
Cauca clasificados como curados o en vigilancia, según criterios
preestablecidos por la Organización Mundial de la Salud (OMS).
Metodología: De la base de datos del Consultorio
Dermatológico del Servicio de Salud del Valle del Cauca se
estudiaron en total 159 pacientes con en |
---|---|
ISSN: | 0120-8322 1657-9534 |
DOI: | 10.25100/cm.v41i.2.697 |